

# PATIENT ALERT CARD

## Apixaban 1 mg/ml Oral Suspension (apixaban)

### Patient Alert Card

Carry this card with you at all times

Show this card to your pharmacist, dentist and any other healthcare professionals that treat you.

I am under anticoagulation treatment with Apixaban 1 mg/ml Oral Suspension to prevent blood clots

Please complete this section or ask your doctor to do it

Name: \_\_\_\_\_

Birth Date: \_\_\_\_\_

Indication: \_\_\_\_\_

Dose: \_\_\_\_\_ mg twice daily

Doctor's Name: \_\_\_\_\_

Doctor's telephone: \_\_\_\_\_

### Information for patients

- Take Apixaban 1 mg/ml Oral Suspension regularly as instructed. If you miss a morning dose, take it as soon as you remember and it may be taken together with the evening dose. A missed evening dose can only be taken during the same evening. Do not take two doses the next morning, instead continue to follow your dosing schedule twice daily as recommended on the next day.
- Do not stop taking Apixaban 1 mg/ml Oral Suspension without talking to your doctor, as you are at risk of suffering from a stroke or other complications.
- Apixaban 1 mg/ml Oral Suspension helps to thin your blood. However, this may increase your risk of bleeding.
- Signs and symptoms of bleeding include bruising or bleeding under the skin, tar-coloured stools, blood in urine, nose-bleed, dizziness, tiredness, paleness or weakness, sudden severe headache, coughing up blood or vomiting blood.
- If the bleeding does not stop on its own, **seek medical attention immediately**.
- If you need surgery or any invasive procedure, inform your doctor that you are taking Apixaban 1 mg/ml Oral Suspension.

### Information for healthcare professionals

- Apixaban 1 mg/ml Oral Suspension is an oral anticoagulant acting by direct selective inhibition of factor Xa.
- Apixaban 1 mg/ml Oral Suspension may increase the risk of bleeding. In case of major bleeding events, it should be stopped immediately.
- Treatment with Apixaban 1 mg/ml Oral Suspension does not require routine monitoring of exposure. A calibrated quantitative anti-Factor Xa assay may be useful in exceptional situations, e.g., overdose and emergency surgery (prothrombin time (PT), international normalised ratio (INR) and activated partial thromboplastin time (aPTT) clotting tests are not recommended) – see SmPC.

An agent to reverse the anti-factor Xa activity of apixaban is available.

Date of preparation: July 2025

Approved by MHRA: Dec 2025